Lv7
4700 积分 2021-12-06 加入
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
4天前
已完结
CAR-T Rapid Manufacturing: Implications on Product and Analytical Testing
22天前
已完结
Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer
26天前
已完结
Large language model-based biological age prediction in large-scale populations
1个月前
已关闭
Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures
1个月前
已完结
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL
2个月前
已关闭
Facts and hopes: CAR-T cell therapy and Immune contexture in Non-Hodgkin Lymphoma
2个月前
已关闭
Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
2个月前
已完结
DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response
2个月前
已关闭
Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line
2个月前
已关闭
Interview with Carlos Caldas
皖公网安备34019202002308
